GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBPP.PFD) » Definitions » Enterprise Value

Regen BioPharma (Regen BioPharma) Enterprise Value : $0.00 Mil (As of May. 15, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Regen BioPharma Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Regen BioPharma's Enterprise Value is $0.00 Mil. Regen BioPharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.82 Mil. Therefore, Regen BioPharma's EV-to-EBIT ratio for today is 0.00.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Regen BioPharma's Enterprise Value is $0.00 Mil. Regen BioPharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.82 Mil. Therefore, Regen BioPharma's EV-to-EBITDA ratio for today is 0.00.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Regen BioPharma's Enterprise Value is $0.00 Mil. Regen BioPharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.24 Mil. Therefore, Regen BioPharma's EV-to-Revenue ratio for today is 0.00.


Regen BioPharma Enterprise Value Historical Data

The historical data trend for Regen BioPharma's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma Enterprise Value Chart

Regen BioPharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regen BioPharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regen BioPharma's Enterprise Value

For the Biotechnology subindustry, Regen BioPharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regen BioPharma's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's Enterprise Value falls into.



Regen BioPharma Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Regen BioPharma's Enterprise Value for the fiscal year that ended in Sep. 2023 is calculated as

Regen BioPharma's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regen BioPharma  (OTCPK:RGBPP.PFD) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Regen BioPharma's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/-0.823
=0.00

Regen BioPharma's current Enterprise Value is $0.00 Mil.
Regen BioPharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.82 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Regen BioPharma's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=0.000/-0.823
=0.00

Regen BioPharma's current Enterprise Value is $0.00 Mil.
Regen BioPharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.82 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Regen BioPharma's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=0.000/0.236
=0.00

Regen BioPharma's current Enterprise Value is $0.00 Mil.
Regen BioPharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regen BioPharma Enterprise Value Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Regen BioPharma (Regen BioPharma) Business Description

Traded in Other Exchanges
Address
4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.